In contrast, the SYK inhibitor fostamatinib, an orally available prodrug that has recently been approved for the treatment of adult patients with chronic immune thrombocytopenia, and the active metabolite R406, had no antitumor effects in tumor-bearing animals when administered via several local routes and in multiple formulations (127–129). This evidence concerns the gene SYK and neoplasm.